Therefore, our data indicated that pharmacological activation of PXR might induce hepatic steatosis through the stimulation of PXR-PPARγ and inhibition of fatty acid β oxidation by regulating PPARα pathways rather than alterations on SREBP1 signaling pathways. The gene discussed is SREBF1; the disease is fatty liver disease.